ArticleACS synthetic biology2025
Design of Specific Peptide Inhibitors of Toxin-Antitoxin-Mediated Antiphage Defense.
Article in ACS synthetic biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synthetically designed anti-defense proteins overcome barriers to bacterial transformation and phage infection.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Toxin-antitoxin (TA) systems are widespread antiphage defense elements in bacteria that may impede successful phage therapy. Phage-encoded inhibitors of these systems have been discovered that enhance phage infection capacity. We used fragment-based design with deep-learning scoring functions to design peptide inhibitors of the toxin RelE. Our peptides extend a fragment of the native RelB antitoxin and are sufficient to inhibit RelE toxicity. Successful inhibitors share a highly conserved binding mode that mimics the native antitoxin but have diverse sequences, with alternative contacts used to form the peptide-protein interface. Designed peptides show different interaction specificities toward RelE family proteins, distinct from the wild-type RelB antitoxin, and inhibit the antiphage defense activity of multiple orthologous RelBE systems. This work showcases the use of structure-based computational design to generate peptide binders that serve as potential counter-defense elements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.